Brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.27). BioDelivery Sciences International posted earnings of $0.58 per share in the same quarter last year, which suggests a negative year over year growth rate of 139.7%. The business is scheduled to report its next quarterly earnings results on Monday, May 21st.
On average, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.74) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.60). For the next financial year, analysts expect that the firm will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.41) to ($0.13). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $9.83 million. BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%.
A number of brokerages recently commented on BDSI. Seaport Global Securities began coverage on shares of BioDelivery Sciences International in a research report on Friday, January 26th. They issued a “buy” rating and a $5.00 target price on the stock. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 14th. ValuEngine cut shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a research report on Thursday, March 15th. Finally, HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $4.25.
NASDAQ:BDSI traded down $0.05 during trading hours on Monday, reaching $2.05. The company’s stock had a trading volume of 201,490 shares, compared to its average volume of 487,098. The stock has a market cap of $122.74, a PE ratio of -5.26 and a beta of 0.44. BioDelivery Sciences International has a 1 year low of $1.55 and a 1 year high of $3.60. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37.
In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 113,876 shares of the firm’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $2.14, for a total value of $243,694.64. Following the sale, the director now owns 319,717 shares of the company’s stock, valued at approximately $684,194.38. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the firm’s stock in a transaction on Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the completion of the sale, the chief financial officer now directly owns 97,731 shares in the company, valued at approximately $204,257.79. The disclosure for this sale can be found here. In the last three months, insiders sold 995,533 shares of company stock worth $2,592,279. Insiders own 7.73% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Royce & Associates LP bought a new stake in BioDelivery Sciences International in the 3rd quarter worth $3,814,000. Broadfin Capital LLC boosted its stake in shares of BioDelivery Sciences International by 5.1% during the 4th quarter. Broadfin Capital LLC now owns 4,634,119 shares of the specialty pharmaceutical company’s stock valued at $13,671,000 after purchasing an additional 223,253 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in shares of BioDelivery Sciences International during the 4th quarter valued at about $201,000. JPMorgan Chase & Co. bought a new stake in shares of BioDelivery Sciences International during the 3rd quarter valued at about $116,000. Finally, Krilogy Financial LLC boosted its stake in shares of BioDelivery Sciences International by 28.8% during the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after purchasing an additional 30,000 shares in the last quarter. 45.84% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/zacks-analysts-anticipate-biodelivery-sciences-international-inc-bdsi-to-post-0-23-earnings-per-share.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.